Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
Ahmed O. Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, Lianchun Xiao, Jean‐Nicolas Vauthey, Sunyoung S. Lee, Betül Gök Yavuz, Yehia I. Mohamed, Aliya Qayyum, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S. Yadav, Courtney Nicholas, Jing Sun, Kanwal Raghav, Asif Rashid, Kristen Carter, Yun Shin Chun, Ching‐Wei D. Tzeng, Divya Sakamuri, Li Xu, Ryan Sun, Vittorio Cristini, Laura Beretta, James C. Yao, Robert A. Wolff, James P. Allison, Padmanee Sharma
Topics & Concepts
NivolumabMedicineIpilimumabOpen labelPerioperativeHepatocellular carcinomaInternal medicineOncologyRandomized controlled trialSurgeryCancerImmunotherapyHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune Response